MedTrace Logo

A Study Of The Effects Of PF-04958242 In Subjects With Age-Related Hearing Loss

NCT01518920 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2019-11-21

No results posted yet for this study

Summary

The objective of this study is to examine the safety, tolerability, and effects on hearing thresholds of two single doses of PF-04958242 and placebo in subjects with age-related hearing loss.

Conditions

  • Hearing Loss, Sensorineural

Interventions

DRUG

PF-04958242

PF-04958242 0.35 mg oral solution

DRUG

PF-04958242

PF-04958242 0.27 mg oral solution

DRUG

Placebo

Placebo oral solution

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Biogen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
50 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2013-02-28
Completion
2013-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01518920 on ClinicalTrials.gov